The longtime veteran of NBC News spoke out about his cancer recently while accepting a prestigious achievement award.
At the Peabody Awards held at the Waldorf Astoria on Monday, Tom Brokaw accepted the Peabody achievement award, and while doing so, talked briefly about his diagnosis of and treatment for multiple myeloma.
"This is a humbling moment for me. If you live long enough these kind of awards come to you and, or, you get cancer. Turns out, I ended up getting both," he told those in attendance. "It’s going to work out. Life is going to be OK because I’m in the enviable position of getting the best treatment in the world and it has made me much more conscious of what a privilege it is to have the kind of job that I have."
Earlier that day, Brokaw told Page Six that his diagnosis last August caught him "blindsided" but that he's confident that he'll do well. Last month he told the Associated Press that his doctors think his treatment will be successful.
Brokaw is 74 years old. He was the anchor for NBC Nightly News from 1982 until he stepped down from the role in 2004. In addition to other work, Brokaw serves as a Special Correspondent for NBC News.
Source: Variety
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...